AstraZeneca (AZN) Announces New Data Demonstrate RSV Immunoprophylaxis With SYNAGIS® (palivizumab) May Result in Reduced Overall Costs
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) today announced new results data which evaluated the cost-effectiveness of SYNAGIS® (palivizumab) for respiratory syncytial virus (RSV) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
